vs

Side-by-side financial comparison of Princeton Bancorp, Inc. (BPRN) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Princeton Bancorp, Inc. is the larger business by last-quarter revenue ($20.7M vs $12.5M, roughly 1.7× Avidity Biosciences, Inc.). Princeton Bancorp, Inc. runs the higher net margin — 29.3% vs -1398.3%, a 1427.6% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 3.6%). Princeton Bancorp, Inc. produced more free cash flow last quarter ($20.6M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 9.1%).

Princeton Bancorp, Inc. is a U.S.-based bank holding company operating through its community banking subsidiary. It offers retail and commercial banking products including deposit accounts, small business loans, consumer loans, mortgages and wealth management services, primarily serving clients across New Jersey and the U.S. mid-Atlantic region.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

BPRN vs RNA — Head-to-Head

Bigger by revenue
BPRN
BPRN
1.7× larger
BPRN
$20.7M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+430.5% gap
RNA
434.0%
3.6%
BPRN
Higher net margin
BPRN
BPRN
1427.6% more per $
BPRN
29.3%
-1398.3%
RNA
More free cash flow
BPRN
BPRN
$177.5M more FCF
BPRN
$20.6M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
9.1%
BPRN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BPRN
BPRN
RNA
RNA
Revenue
$20.7M
$12.5M
Net Profit
$6.1M
$-174.4M
Gross Margin
Operating Margin
38.2%
-1513.5%
Net Margin
29.3%
-1398.3%
Revenue YoY
3.6%
434.0%
Net Profit YoY
16.3%
-117.0%
EPS (diluted)
$0.89
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BPRN
BPRN
RNA
RNA
Q4 25
$20.7M
Q3 25
$21.5M
$12.5M
Q2 25
$21.1M
$3.8M
Q1 25
$20.9M
$1.6M
Q4 24
$20.0M
$3.0M
Q3 24
$19.2M
$2.3M
Q2 24
$18.1M
$2.0M
Q1 24
$17.4M
$3.5M
Net Profit
BPRN
BPRN
RNA
RNA
Q4 25
$6.1M
Q3 25
$6.5M
$-174.4M
Q2 25
$688.0K
$-157.3M
Q1 25
$5.4M
$-115.8M
Q4 24
$5.2M
$-102.3M
Q3 24
$-4.5M
$-80.4M
Q2 24
$5.1M
$-70.8M
Q1 24
$4.3M
$-68.9M
Operating Margin
BPRN
BPRN
RNA
RNA
Q4 25
38.2%
Q3 25
38.5%
-1513.5%
Q2 25
2.8%
-4448.7%
Q1 25
32.9%
-8360.9%
Q4 24
34.0%
-4069.6%
Q3 24
-29.1%
-4200.9%
Q2 24
34.1%
-4040.4%
Q1 24
31.0%
-2178.6%
Net Margin
BPRN
BPRN
RNA
RNA
Q4 25
29.3%
Q3 25
30.0%
-1398.3%
Q2 25
3.3%
-4089.3%
Q1 25
25.7%
-7360.0%
Q4 24
26.1%
-3439.5%
Q3 24
-23.3%
-3441.7%
Q2 24
28.4%
-3461.8%
Q1 24
24.9%
-1943.4%
EPS (diluted)
BPRN
BPRN
RNA
RNA
Q4 25
$0.89
Q3 25
$0.95
$-1.27
Q2 25
$0.10
$-1.21
Q1 25
$0.77
$-0.90
Q4 24
$0.75
$-0.80
Q3 24
$-0.68
$-0.65
Q2 24
$0.80
$-0.65
Q1 24
$0.68
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BPRN
BPRN
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$270.7M
$1.9B
Total Assets
$2.3B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BPRN
BPRN
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
BPRN
BPRN
RNA
RNA
Q4 25
Q3 25
$0
Q2 25
$10.0M
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BPRN
BPRN
RNA
RNA
Q4 25
$270.7M
Q3 25
$266.6M
$1.9B
Q2 25
$261.9M
$1.2B
Q1 25
$267.0M
$1.3B
Q4 24
$262.0M
$1.4B
Q3 24
$261.5M
$1.5B
Q2 24
$244.8M
$1.2B
Q1 24
$241.8M
$830.9M
Total Assets
BPRN
BPRN
RNA
RNA
Q4 25
$2.3B
Q3 25
$2.2B
$2.1B
Q2 25
$2.2B
$1.4B
Q1 25
$2.3B
$1.5B
Q4 24
$2.3B
$1.6B
Q3 24
$2.4B
$1.6B
Q2 24
$2.0B
$1.3B
Q1 24
$2.0B
$951.5M
Debt / Equity
BPRN
BPRN
RNA
RNA
Q4 25
Q3 25
0.00×
Q2 25
0.04×
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BPRN
BPRN
RNA
RNA
Operating Cash FlowLast quarter
$21.5M
$-156.2M
Free Cash FlowOCF − Capex
$20.6M
$-156.9M
FCF MarginFCF / Revenue
99.3%
-1257.6%
Capex IntensityCapex / Revenue
4.3%
5.7%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$29.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BPRN
BPRN
RNA
RNA
Q4 25
$21.5M
Q3 25
$4.9M
$-156.2M
Q2 25
$3.1M
$-199.7M
Q1 25
$1.3M
$-124.8M
Q4 24
$14.7M
$-99.9M
Q3 24
$1.2M
$-65.6M
Q2 24
$4.3M
$-65.0M
Q1 24
$4.8M
$-70.4M
Free Cash Flow
BPRN
BPRN
RNA
RNA
Q4 25
$20.6M
Q3 25
$4.7M
$-156.9M
Q2 25
$2.9M
$-203.0M
Q1 25
$1.1M
$-128.6M
Q4 24
$13.2M
$-103.8M
Q3 24
$766.0K
$-67.3M
Q2 24
$3.9M
$-65.5M
Q1 24
$4.8M
$-71.3M
FCF Margin
BPRN
BPRN
RNA
RNA
Q4 25
99.3%
Q3 25
21.6%
-1257.6%
Q2 25
13.7%
-5277.1%
Q1 25
5.0%
-8174.3%
Q4 24
65.9%
-3491.0%
Q3 24
4.0%
-2881.8%
Q2 24
21.8%
-3204.6%
Q1 24
27.3%
-2012.3%
Capex Intensity
BPRN
BPRN
RNA
RNA
Q4 25
4.3%
Q3 25
1.1%
5.7%
Q2 25
1.2%
86.9%
Q1 25
1.0%
238.6%
Q4 24
7.6%
131.7%
Q3 24
2.2%
72.9%
Q2 24
2.1%
26.0%
Q1 24
0.4%
25.8%
Cash Conversion
BPRN
BPRN
RNA
RNA
Q4 25
3.54×
Q3 25
0.76×
Q2 25
4.57×
Q1 25
0.23×
Q4 24
2.82×
Q3 24
Q2 24
0.84×
Q1 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons